Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?
- PMID: 27312437
- DOI: 10.1016/j.kint.2016.05.002
Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?
Abstract
Posttrial follow-up of participants randomized to intensive versus standard glycemic control in the ADVANCE trial has demonstrated a significant benefit of intensive glycemic control on the risk of end-stage renal disease. In a more detailed analysis, intensive glycemic control appears to be of benefit only before the development of clinically evident kidney disease or in patients with documented early-stage chronic kidney disease.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.Diabetes Care. 2016 May;39(5):694-700. doi: 10.2337/dc15-2322. Epub 2016 Mar 22. Diabetes Care. 2016. PMID: 27006512 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical